

Intravenous Immunoglobulin Market 2026

<https://marketpublishers.com/r/IAEE7C2E252EEN.html>

Date: February 2026

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: IAEE7C2E252EEN

Abstracts

The Intravenous Immunoglobulin Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Intravenous Immunoglobulin Market.

This report delivers a comprehensive overview of the Intravenous Immunoglobulin Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Intravenous Immunoglobulin Market. The Intravenous Immunoglobulin Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Intravenous Immunoglobulin Market Scope:

Major Highlights

This report delivers a comprehensive overview of the Intravenous Immunoglobulin Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Intravenous Immunoglobulin Market. The Intravenous Immunoglobulin Market size, estimates, and forecasts are

provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Route of Administration
- 3.2. Market Snippet by Clinical Trial Type Phase
- 3.3. Market Snippet by End-User
- 3.4. Market Snippet by Application
- 3.5. Market Snippet by Region

4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET-MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increase in primary immune deficiency diseases to drive the intravenous immunoglobulin market
 - 4.1.1.2. Increase in Research and Development
 - 4.1.1.3. Rise in Geriatric Population.
 - 4.1.2. Restraints:
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Value Chain Analysis
- 5.4. PEST Analysis
- 5.5. Pricing Analysis
- 5.6. Regulatory Analysis
- 5.7. Reimbursement Analysis
- 5.8. Unmet Needs

5.9. Patent Trends

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market

- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario

6.2. Pricing Dynamics Amid Covid-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During Pandemic

6.5. Manufacturers Strategic Initiatives

6.6. Conclusion

7. BY ROUTE OF ADMINISTRATION

7.1. Introduction

7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment

7.3. Market Attractiveness Index, By Route of Administration Segment

- 7.3.1. Intravenous*
 - 7.3.1.1. Introduction
 - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Subcutaneous

8. BY CLINICAL TRIAL TYPE PHASE

8.1. Introduction

8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase Segment

8.3. Market Attractiveness Index, By Clinical Trial Type Phase Segment

- 8.3.1. Immunoglobulin G*
 - 8.3.1.1. Introduction
 - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Immunoglobulin A
- 8.3.3. Immunoglobulin M
- 8.3.4. Immunoglobulin E
- 8.3.5. Immunoglobulin D

9. BY END-USER

9.1. Introduction

9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment

9.3. Market Attractiveness Index, By End-User Segment

9.3.1. Hospitals*

9.3.1.1. Introduction

9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

9.3.2. Clinics

9.3.3. Homecare

9.3.4. Others

10. BY APPLICATION

10.1. Introduction

10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment

10.3. Market Attractiveness Index, By Application Segment

10.3.1. Hypogammaglobulinemia*

10.3.1.1. Introduction

10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

10.3.2. Chronic Inflammatory Demyelinating Polyneuropathy

10.3.3. Immunodeficiency Disease

10.3.4. Myasthenia Gravis

10.3.5. Multifocal Motor Neuropathy

10.3.6. Idiopathic Thrombocytopenic Purpura (ITP)

10.3.7. Inflammatory Myopathies

10.3.8. Specific Antibody Deficiency

10.3.9. Guillain–Barré Syndrome

10.3.10. Others

11. BY REGION

11.1. Introduction

11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

11.3. Market Attractiveness Index, By Region

11.4. North America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. U.S.

11.4.7.2. Canada

11.4.7.3. Mexico

11.5. Europe

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase

11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. Germany

11.5.7.2. U.K.

11.5.7.3. France

11.5.7.4. Italy

11.5.7.5. Spain

11.5.7.6. Rest of Europe

11.6. South America

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase

11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.6.7.1. Brazil

11.6.7.2. Argentina

11.6.7.3. Rest of South America

11.7. Asia Pacific

- 11.7.1. Introduction
- 11.7.2. Key Region-Specific Dynamics
- 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
- 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 11.7.7.1. China
 - 11.7.7.2. India
 - 11.7.7.3. Japan
 - 11.7.7.4. Australia
 - 11.7.7.5. Rest of Asia Pacific
- 11.8. Middle East and Africa
 - 11.8.1. Introduction
 - 11.8.2. Key Region-Specific Dynamics
 - 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
 - 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
 - 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
 - 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET - COMPANY PROFILES

- 13.1. Bharat Serums and Vaccines Limited*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Key Highlights
 - 13.1.4. Financial Overview
- 13.2. Biotest AG

- 13.3. China Biologic Products, Inc.
- 13.4. Guizhou Taibang Biological Products Co., Ltd
- 13.5. CSL Limited
- 13.6. Grifols, S.A.
- 13.7. Hualan Biological Engineering Inc.
- 13.8. Kedrion S.p.A.
- 13.9. LFB Group
- 13.10. Octapharma AG (*LIST NOT EXHAUSTIVE*)

14. PREMIUM INSIGHTS

15. DATAM INTELLIGENCE

- 15.1. Appendix
- 15.2. About Us and Services
- 15.3. Contact Us

I would like to order

Product name: Intravenous Immunoglobulin Market 2026

Product link: <https://marketpublishers.com/r/IAEE7C2E252EEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IAEE7C2E252EEN.html>